Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.42 |
| ▸ | PER2 | O15055 | 1/20 | 0.41 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.41 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8157650 | 0.80 | BRD4 (0.50) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL3571552 | 0.79 | CA9 (0.39) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL23733163 | 0.73 | FFAR4 (0.42) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL9255195 | 0.73 | CACNA1H (0.43) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL8972288 | 0.73 | PER2 (0.51) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL6714419 | 0.73 | PER2 (0.51) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL3575520 | 0.73 | RYR2 (0.51) | CA2NOTUMDRD2DRD1DRD4 | |
| SCHEMBL28194834 | 0.72 | FFAR4 (0.44) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL19673967 | 0.72 | FFAR4 (0.44) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL28207011 | 0.72 | FFAR4 (0.44) | FFAR4FFAR1PER2CRY1CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190778-A1 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENTARSASAG (HU) | 2010-07-29 | — | — | US | disclosed |
| EP-2064197-A2 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008020256-A2 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | EGIS GYÓGYSZERGYÁR_Nyilvánosan Müködö Részvénytársaság (HU) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190778-A1 | 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE | TDO2, DHODH, DHPS | FFAR4 3586/4885FFAR1 3652/4885PER2 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.